Compass Therapeutics, Inc.

NASDAQ:CMPX

Biotechnology

Healthcare
$0.61 -1.46%

-$0.03 today

Market cap
$109.26M
Beta
0.74
P/E (TTM)
-5.5
EPS (TTM)
-$0.37
52W Low $1.61High $6.88

Volume 2.90M

Average 7.64M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$49.14M

FY 2025 · Annual

Investing Cash Flow

-$93.31M

FY 2025 · Annual

Financing Cash Flow

$129.61M

FY 2025 · Annual

+647.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(82.18M)(39.23M)(42.49M)(49.38M)(66.49M)
Depreciation & Amortization1.62M1.9M1.89M1.75M(1.4M)
Deferred Income Tax50.58M0000
Stock-Based Compensation4.03M5.33M6.12M8.56M8.37M
Change in Working Capital6.25M(1.26M)(2.91M)(4.14M)9.18M
Accounts Receivables00000
Inventory00000
Accounts Payables(194K)2.52M708K(1.84M)(664K)
Other Working Capital6.44M(3.78M)(3.62M)(2.3M)9.84M
Other Non-Cash Items41K(871K)5.97M(1.65M)1.2M
Operating Cash Flow(19.67M)(34.13M)(40.62M)(44.86M)(49.14M)
Capital Expenditures(1.57M)(212K)(30K)(44K)(25K)
Acquisitions (Net)116K176K000
Purchases of Investments0(200.12M)(155.42M)(88.16M)(194.56M)
Sales of Investments048.96M182.41M134.97M101.28M
Other Investing Activities(318K)(150.99K)27K00
Investing Cash Flow(1.77M)(151.2M)26.97M46.77M(93.31M)
Debt Repayment———00
Common Stock Issued128.27M76.24M3.09M18.11M130.64M
Common Stock Repurchased00(159)00
Dividends Paid00000
Other Financing Activities(281K)(480K)(159K)(775K)(1.03M)
Financing Cash Flow118.61M75.76M2.94M17.34M129.61M
Effect of Forex Changes00000
Net Change in Cash97.18M(109.57M)(10.72M)19.26M(12.84M)
Free Cash Flow(21.23M)(34.34M)(40.65M)(44.9M)(49.17M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$66.5M
+ D&A-$1.4M
+ Stock-Based Comp$8.4M
+ Deferred Tax$0
+ Working Capital$9.2M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$49.1M
- Capex-$25.0K
= Free Cash Flow-$49.2M

Analysis

FY2025 free cash flow is -$49.2M. FCF conversion is 73.9% of net income. Operating cash flow was -$49.1M, with capex of -$25.0K. The largest bridge item is Working Capital at $9.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipOct 2, 2026
4Statement of changes in beneficial ownershipSep 25, 2026

Does CMPX generate free cash flow?

Compass Therapeutics, Inc. (CMPX) generated -$49.17M of free cash flow in fiscal 2025.

How much operating cash flow does CMPX produce?

Operating cash flow was -$49.14M, before capital expenditures of $25,000.00.